CG Oncology Quarterly Cash Flow Statement
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CG Oncology free cash flow
In the quarter ended Jun 30, 2026, CG Oncology generated -$46.4 million of operating cash flow and spent $468,000 on capital expenditures. That left free cash flow of -$46.9 million, a free-cash-flow margin of -4052.0% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
CG Oncology cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -79.06M | -60.20M | -41.31M | -43.81M | -41.43M | -34.45M | -31.80M | -20.41M | -18.90M | -16.93M | -16.55M | -11.77M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 850.00K | 841.00K | 849.00K | 416.00K | 156.00K | 24.00K | 0 | 21.00K | 7.00K | 4.00K | 4.00K | 5.00K |
| Stock-Based Compensation | 14.33M | 6.47M | 7.19M | 7.33M | 7.01M | 5.15M | 4.99M | 2.65M | 2.25M | 1.52M | 778.00K | 394.00K |
| Change in Working Capital | 3.79M | 1.01M | -5.41M | 1.22M | 199.00K | 615.00K | 1.76M | -370.00K | -169.00K | -2.75M | 1.38M | -1.27M |
| Operating Cash Flow | -46.41M | -56.94M | -36.22M | -38.89M | -27.96M | -29.28M | -20.66M | -15.92M | -16.12M | -26.01M | -14.64M | -12.26M |
| Capital Expenditures | -468.00K | -304.00K | -7.00K | -97.00K | -14.00K | -16.00K | -209.00K | 1.00K | -14.00K | -12.00K | — | — |
| Investing Cash Flow | 30.43M | -334.85M | -75.50M | 15.04M | 1.41M | -186.77M | 10.90M | 32.01M | -36.23M | -307.44M | 15.53M | -161.39M |
| Financing Cash Flow | 1.92M | 393.00M | 99.07M | 54.37M | -296.00K | 450.00K | 223.41M | 2.17M | 40.00K | 402.66M | -2.90M | 105.88M |
| Net Change in Cash | -14.06M | 1.21M | -12.65M | 30.52M | -26.85M | -215.60M | 213.66M | 18.25M | -52.31M | 69.20M | -2.01M | -67.77M |
| Free Cash Flow | -46.88M | -57.25M | -36.22M | -38.99M | -27.97M | -29.29M | -20.87M | -15.92M | -16.13M | -26.02M | -14.64M | -12.26M |
This table shows 12 quarterly periods of CG Oncology's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CGON's reporting calendar. What is a cash flow statement?